L3VLUP

APGE in the 13F filings

Apogee Therapeutics Inc · CUSIP 03770N101

Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 14 Nov 2023
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 0 listed it in both
Shares listed
320,000
combined, among listed positions
Reported value
$6.8m
combined, at the quarter end

Managers listing APGE in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Woodline Partners LP310,000$6.6m0.08%Newnew14 Nov 2023 (the filing on sec.gov)
Davidson Kempner Capital Management LP10,000$213kunder 0.1%Newnew14 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

There is no earlier quarter on file to compare with.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 9 in Q2 2026

Tracked managers listing it, at least.

035810Q3 2023Q1 2024Q3 2024Q1 2025Q3 2025Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
APGE by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20232$6.8mn.a.n.a.
Q4 20233$32m21
Q1 20246$699m51
Q2 20242$169m21
Q3 20243$382m30
Q4 20244$311m31
Q1 20254$323m31
Q2 20253$257m12
Q3 20251$188m11
Q4 20255$1.2bn1210
Q1 20267$1.5bn1313
Q2 20269$829m2212

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

Choose a stock to compare with APGE →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own APGE, latest filings →Back to the 13F Explorer →